BioCentury | Oct 29, 2020
Product Development

Flagship’s Senda builds on Kintai’s microbe-mimicking pipeline with plant and bacteria-based delivery modalities

...reins of one of the four companies, Kintai Therapeutics Inc....
...millionInvestors: Flagship PioneeringCEO: Guillaume Pfeffer Karen Tkach Tuzman Flagship Pioneering Kintai Therapeutics Inc. microbiome interspecies...
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

Liquid biopsy company Thrive Earlier Detection Corp. hired Sam Asgarian as CMO, Frank Diehl as EVP of product solutions and Dina Ciarimboli as chief legal officer. Before joining Thrive, Asgarian was VP of the transformation health product organization at...
BioCentury | Jul 22, 2020
Management Tracks

Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

...a GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) alum. Tak, a former GSK chief immunology officer, recently departed Kintai Therapeutics Inc....
BioCentury | Jul 16, 2020
Management Tracks

Flagship picks Pfefer to lead Kintai, succeeding Tak

...has left his role as venture partner at the firm. The leadership change comes as Kintai Therapeutics Inc....
...had been CSO of Senda, will be CSO of the combined company. Paul Bonanos, Associate Editor Flagship Pioneering Kintai Therapeutics Inc. Senda...
BioCentury | Feb 29, 2020
Management Tracks

Brandicourt joins Alnylam's board: plus Bayer, Jazz, Halozyme, Arena, Aurinia, Adverum, Neoleukin, Centogene, Epirium, Insilico, Nouscom, Eloxx, Nordic, Summit,

...development and appointed Maxine Gowen as board director. Lee was VP of preclinical development at Kintai Therapeutics Inc....
BioCentury | Jan 23, 2020
Preclinical News

Kintai reveals preclinical validation for its microbiome-inspired small molecules, prioritizes obesity

...one way to tap into the microbiome’s links to human pathology without touching the bacteria. Kintai Therapeutics Inc....
...obesity next year. - Staff Writer Elizabeth S. Eaton contributed to this article. Lauren Martz, Senior Editor Kintai Therapeutics Inc. Microbiome...
BioCentury | Jan 10, 2020
Company News

Management tracks: COO, CMO depart as Solid restructures; plus Abeona, Millendo, Immuneering, Akouos, Kintai, Macrophage, Selexis, Prime

...AAV)-based gene therapies for sensorineural hearing loss (See “Sound Story” ). Enteric signaling network company Kintai Therapeutics Inc....
...accounts group at Medco Health Solutions Inc. Hongjiang Li, Staff Writer and Sandi Wong, Assistant Editor Akouos Inc. Kintai Therapeutics Inc. Macrophage...
BioCentury | Nov 2, 2019
Company News

Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

...1, and begin a search for an EVP and COO to expand its executive team. Kintai Therapeutics Inc....
...patient value and product strategy at Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK). BioCentury Staff Actimed Therapeutics Ltd. Genmab A/S Kintai Therapeutics Inc. Aerie...
BioCentury | Oct 23, 2019
Company News

Management tracks: Amgen’s Meline retiring; plus BlackThorn, Rheos, Novartis, Kintai, Myriad, Avrobio, Oncorus, Moberg, Achilles and Aerpio

...Feb. 28. Moroney co-founded MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and was its CEO until Sept. 1. Kintai Therapeutics Inc....
...company has begun to explore strategic alternatives, including a possible sale. BioCentury Staff BlackThorn Therapeutics Inc. Rheos Medicines Inc. Kintai Therapeutics Inc. Novartis...
BioCentury | Sep 26, 2019
Company News

Omega: Flagship’s latest venture into the chromatin white space

...microbiome. Flagship has carved up the microbiome space across four portfolio companies, most recently launching Kintai Therapeutics Inc....
Items per page:
1 - 10 of 15
BioCentury | Oct 29, 2020
Product Development

Flagship’s Senda builds on Kintai’s microbe-mimicking pipeline with plant and bacteria-based delivery modalities

...reins of one of the four companies, Kintai Therapeutics Inc....
...millionInvestors: Flagship PioneeringCEO: Guillaume Pfeffer Karen Tkach Tuzman Flagship Pioneering Kintai Therapeutics Inc. microbiome interspecies...
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

Liquid biopsy company Thrive Earlier Detection Corp. hired Sam Asgarian as CMO, Frank Diehl as EVP of product solutions and Dina Ciarimboli as chief legal officer. Before joining Thrive, Asgarian was VP of the transformation health product organization at...
BioCentury | Jul 22, 2020
Management Tracks

Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

...a GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) alum. Tak, a former GSK chief immunology officer, recently departed Kintai Therapeutics Inc....
BioCentury | Jul 16, 2020
Management Tracks

Flagship picks Pfefer to lead Kintai, succeeding Tak

...has left his role as venture partner at the firm. The leadership change comes as Kintai Therapeutics Inc....
...had been CSO of Senda, will be CSO of the combined company. Paul Bonanos, Associate Editor Flagship Pioneering Kintai Therapeutics Inc. Senda...
BioCentury | Feb 29, 2020
Management Tracks

Brandicourt joins Alnylam's board: plus Bayer, Jazz, Halozyme, Arena, Aurinia, Adverum, Neoleukin, Centogene, Epirium, Insilico, Nouscom, Eloxx, Nordic, Summit,

...development and appointed Maxine Gowen as board director. Lee was VP of preclinical development at Kintai Therapeutics Inc....
BioCentury | Jan 23, 2020
Preclinical News

Kintai reveals preclinical validation for its microbiome-inspired small molecules, prioritizes obesity

...one way to tap into the microbiome’s links to human pathology without touching the bacteria. Kintai Therapeutics Inc....
...obesity next year. - Staff Writer Elizabeth S. Eaton contributed to this article. Lauren Martz, Senior Editor Kintai Therapeutics Inc. Microbiome...
BioCentury | Jan 10, 2020
Company News

Management tracks: COO, CMO depart as Solid restructures; plus Abeona, Millendo, Immuneering, Akouos, Kintai, Macrophage, Selexis, Prime

...AAV)-based gene therapies for sensorineural hearing loss (See “Sound Story” ). Enteric signaling network company Kintai Therapeutics Inc....
...accounts group at Medco Health Solutions Inc. Hongjiang Li, Staff Writer and Sandi Wong, Assistant Editor Akouos Inc. Kintai Therapeutics Inc. Macrophage...
BioCentury | Nov 2, 2019
Company News

Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

...1, and begin a search for an EVP and COO to expand its executive team. Kintai Therapeutics Inc....
...patient value and product strategy at Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK). BioCentury Staff Actimed Therapeutics Ltd. Genmab A/S Kintai Therapeutics Inc. Aerie...
BioCentury | Oct 23, 2019
Company News

Management tracks: Amgen’s Meline retiring; plus BlackThorn, Rheos, Novartis, Kintai, Myriad, Avrobio, Oncorus, Moberg, Achilles and Aerpio

...Feb. 28. Moroney co-founded MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and was its CEO until Sept. 1. Kintai Therapeutics Inc....
...company has begun to explore strategic alternatives, including a possible sale. BioCentury Staff BlackThorn Therapeutics Inc. Rheos Medicines Inc. Kintai Therapeutics Inc. Novartis...
BioCentury | Sep 26, 2019
Company News

Omega: Flagship’s latest venture into the chromatin white space

...microbiome. Flagship has carved up the microbiome space across four portfolio companies, most recently launching Kintai Therapeutics Inc....
Items per page:
1 - 10 of 15